48
Participants
Start Date
October 25, 2023
Primary Completion Date
October 31, 2024
Study Completion Date
June 30, 2025
OpSCF
Monoclonal Antibody
Placebo
Formulation buffer without active agent
OpSCF (Open Label Extension)
Subjects may continue on an Open Label Extension after completing the 16-week randomized portion of the study
Forest Hills Dermatology Group, Kew Gardens
RM Medical Research, Miami Lakes
Skin Research of South Florida, Miami
Skin Care Research, Boca Raton
Cahaba Dermatology & Skin Health Center, Birmingham
Advanced Clinical Research Institute, Tampa
DS Research of Kentucky, Louisville
Options Research Group, West Lafayette
Oakland Hills Dermatology P.C, Auburn Hills
Saginaw Bay Dermatology, Bay City
Arlington Dermatology, Rolling Meadows
Rodgers Dermatology, Frisco
Skin Cancer and Dermatology Institute, Reno
Axon Clinical Research, Inglewood
Unison Clinical Trials, Sherman Oaks
University Clinical Trials, San Diego
First OC Dermatology Research, Fountain Valley
Dermatology Of Seattle, Bellevue
Oshawa Clinic Dermatology Trials, Oshawa
Research Toronto, Toronto
Innovaderm Research Inc, Montreal
Centre de Recherche Saint-Louis, Québec
Lead Sponsor
Collaborators (1)
Innovaderm Research Inc.
OTHER
Opsidio, LLC
INDUSTRY